Exploring TMT. To explore a different substance…

Names:
MCPA
TMT
3,4,5-Trimethoxytranylcypromine
trans-2-(3,4,5-Trimethoxyphenyl)cyclopropylamine
IUPAC names:
2-(3,4,5-Trimethoxyphenyl)cyclopropan-1-amine
2-(3,4,5-Trimethoxyphenyl)cyclopropanamine
229 · C12H17NO3 · 223.268
InChI=1S/C12H17NO3/c1-14-10-4-7(8-6-9(8)13)5-11(15-2)12(10)16-3/h4-5,8-9H,6,13H2,1-3H3
HNYWYOQSLRJIMG-UHFFFAOYSA-N This stereoisomer Any stereoisomer

Arvidsson, L; Johansson, AM; Hacksell, U; Nilsson, JLG; Svensson, K; Hjorth, S; Magnusson, T; Carlsson, A; Lindberg, P; Andersson, B; Sanchez, D; Wikstrõm, H; Sundell, S. N,N-Dialkylated monophenolic trans-2-phenylcyclopropylamines: Novel central 5-hydroxytryptamine receptor agonists. J. Med. Chem., 1 Jan 1988, 31 (1), 92–99. 1.2 MB. https://doi.org/10.1021/jm00396a014

Cooper, PD. Stereospecific synthesis of cis- and trans-2-(3,4,5-trimethoxyphenyl)-cyclopropylamines. Can. J. Chem., 1 Dec 1970, 48 (24), 3882–3888. 452 kB. https://doi.org/10.1139/v70-653

Walters, GC; Cooper, PD. Alicyclic analogue of mescaline. Nature, 20 Apr 1968, 218 (5138), 298–300. 3.1 MB. https://doi.org/10.1038/218298a0

Brimblecombe, RW; Pinder, RM. Hallucinogenic agents, Wright-Scientechnica, Bristol, UK, 1 Jan 1975. 46.2 MB.

Nichols, DE. Chemistry and structure–activity relationships of psychedelics. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 1-43. 2.6 MB. https://doi.org/10.1007/7854_2017_475 #64

Nichols, DE. Structure-activity relationships of serotonin 5-HT2A agonists. WIREs Membr. Transp. Signal, 1 Sep 2012, 1 (5), 559-579. 573 kB. https://doi.org/10.1002/wmts.42 #59

Nichols, DE. Medicinal chemistry and structure-activity relationships. In Amphetamine and its Analogs; Cho, AK; Segal, DS, Eds., Academic Press, San Diego, CA, 1994; pp 3–41. 6.9 MB. #45

Nichols, DE; Weintraub, HJR; Pfister, WR; Yim, GKW. The use of rigid analogues to probe hallucinogen receptors. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1978; pp 70–83. 717 kB. #1

MDHOET
MEDA
N-Me-MMDA-2 · METHYL-MMDA-2
233
4C-MMDA-2
EMDA-2
327
Anhalinine
Anhalidine
Isoanhalidine
Anhalonidine
Isoanhalonidine
MMDMA
2C-pKet
M-hemiFLY
N-iPr-DHA-βk
N,N-Me-2,5-DMPEA-βk
2,5-DMMA-βk
2-HO-N-Me-5-EA-βk
4C-3a
DOHM
TMCPA
α-Et-Lophophine
HO-DOMAI
β-MeO-MDMA
V · Viscaline
bk-MBDB-M2
bk-MBDB-M1
β-OH-MBDB
β-OH-MDEA
bk-MDEA-M1
bk-MDEA-M2
3,4-DMOMC
2,4-DMOMC
bk-DOM
bk-2C-E
Tomscaline
EFLEA
16 July 2018 · Creative Commons BY-NC-SA ·